The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Pharmacogenomics Technology (Theranostics & CDx) Market Research Report 2025
Synopsis
The global Pharmacogenomics Technology (Theranostics & CDx) market was valued at US$ 9591.9 million in 2023 and is anticipated to reach US$ 25330 million by 2030, witnessing a CAGR of 14.7% during the forecast period 2024-2030.
Global Pharmacogenomics Technology (Theranostics & CDx) key players include Illumina, F. Hoffmann-La Roche, Agilent, Abbott, Thermo Fisher Scientific etc. Global top three players hold a share over 65%. North America is the largest market, with a share about 40%, followed by Europe and China, both have a share about 40 percent.
This report aims to provide a comprehensive presentation of the global market for Pharmacogenomics Technology (Theranostics & CDx), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharmacogenomics Technology (Theranostics & CDx).
Report Scope
The Pharmacogenomics Technology (Theranostics & CDx) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pharmacogenomics Technology (Theranostics & CDx) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pharmacogenomics Technology (Theranostics & CDx) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Illumina
F. Hoffmann-La Roche
Agilent
Abbott
Thermo Fisher Scientific
Qiagen
Guardant Health
MGI Tech
Amoy Diagnostics
BGI Group
Segment by Type
Instruments
Reagents and Consumables
Other
Segment by Application
Tumour
Diabetes
Mental Illness
Cardiovascular Disease
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pharmacogenomics Technology (Theranostics & CDx) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Pharmacogenomics Technology (Theranostics & CDx) market was valued at US$ 9591.9 million in 2023 and is anticipated to reach US$ 25330 million by 2030, witnessing a CAGR of 14.7% during the forecast period 2024-2030.
Global Pharmacogenomics Technology (Theranostics & CDx) key players include Illumina, F. Hoffmann-La Roche, Agilent, Abbott, Thermo Fisher Scientific etc. Global top three players hold a share over 65%. North America is the largest market, with a share about 40%, followed by Europe and China, both have a share about 40 percent.
This report aims to provide a comprehensive presentation of the global market for Pharmacogenomics Technology (Theranostics & CDx), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharmacogenomics Technology (Theranostics & CDx).
Report Scope
The Pharmacogenomics Technology (Theranostics & CDx) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pharmacogenomics Technology (Theranostics & CDx) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pharmacogenomics Technology (Theranostics & CDx) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Illumina
F. Hoffmann-La Roche
Agilent
Abbott
Thermo Fisher Scientific
Qiagen
Guardant Health
MGI Tech
Amoy Diagnostics
BGI Group
Segment by Type
Instruments
Reagents and Consumables
Other
Segment by Application
Tumour
Diabetes
Mental Illness
Cardiovascular Disease
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pharmacogenomics Technology (Theranostics & CDx) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Instruments
1.2.3 Reagents and Consumables
1.2.4 Other
1.3 Market by Application
1.3.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Tumour
1.3.3 Diabetes
1.3.4 Mental Illness
1.3.5 Cardiovascular Disease
1.3.6 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Perspective (2019-2030)
2.2 Pharmacogenomics Technology (Theranostics & CDx) Growth Trends by Region
2.2.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size by Region (2019-2024)
2.2.3 Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Region (2025-2030)
2.3 Pharmacogenomics Technology (Theranostics & CDx) Market Dynamics
2.3.1 Pharmacogenomics Technology (Theranostics & CDx) Industry Trends
2.3.2 Pharmacogenomics Technology (Theranostics & CDx) Market Drivers
2.3.3 Pharmacogenomics Technology (Theranostics & CDx) Market Challenges
2.3.4 Pharmacogenomics Technology (Theranostics & CDx) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pharmacogenomics Technology (Theranostics & CDx) Players by Revenue
3.1.1 Global Top Pharmacogenomics Technology (Theranostics & CDx) Players by Revenue (2019-2024)
3.1.2 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Players (2019-2024)
3.2 Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Pharmacogenomics Technology (Theranostics & CDx) Revenue
3.4 Global Pharmacogenomics Technology (Theranostics & CDx) Market Concentration Ratio
3.4.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pharmacogenomics Technology (Theranostics & CDx) Revenue in 2023
3.5 Pharmacogenomics Technology (Theranostics & CDx) Key Players Head office and Area Served
3.6 Key Players Pharmacogenomics Technology (Theranostics & CDx) Product Solution and Service
3.7 Date of Enter into Pharmacogenomics Technology (Theranostics & CDx) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Pharmacogenomics Technology (Theranostics & CDx) Breakdown Data by Type
4.1 Global Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size by Type (2019-2024)
4.2 Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Type (2025-2030)
5 Pharmacogenomics Technology (Theranostics & CDx) Breakdown Data by Application
5.1 Global Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size by Application (2019-2024)
5.2 Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size (2019-2030)
6.2 North America Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2019-2024)
6.4 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size (2019-2030)
7.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2019-2024)
7.4 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size (2019-2030)
8.2 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2019-2024)
8.4 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size (2019-2030)
9.2 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2019-2024)
9.4 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size (2019-2030)
10.2 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2019-2024)
10.4 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Illumina
11.1.1 Illumina Company Detail
11.1.2 Illumina Business Overview
11.1.3 Illumina Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.1.4 Illumina Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2019-2024)
11.1.5 Illumina Recent Development
11.2 F. Hoffmann-La Roche
11.2.1 F. Hoffmann-La Roche Company Detail
11.2.2 F. Hoffmann-La Roche Business Overview
11.2.3 F. Hoffmann-La Roche Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.2.4 F. Hoffmann-La Roche Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2019-2024)
11.2.5 F. Hoffmann-La Roche Recent Development
11.3 Agilent
11.3.1 Agilent Company Detail
11.3.2 Agilent Business Overview
11.3.3 Agilent Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.3.4 Agilent Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2019-2024)
11.3.5 Agilent Recent Development
11.4 Abbott
11.4.1 Abbott Company Detail
11.4.2 Abbott Business Overview
11.4.3 Abbott Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.4.4 Abbott Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2019-2024)
11.4.5 Abbott Recent Development
11.5 Thermo Fisher Scientific
11.5.1 Thermo Fisher Scientific Company Detail
11.5.2 Thermo Fisher Scientific Business Overview
11.5.3 Thermo Fisher Scientific Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.5.4 Thermo Fisher Scientific Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2019-2024)
11.5.5 Thermo Fisher Scientific Recent Development
11.6 Qiagen
11.6.1 Qiagen Company Detail
11.6.2 Qiagen Business Overview
11.6.3 Qiagen Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.6.4 Qiagen Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2019-2024)
11.6.5 Qiagen Recent Development
11.7 Guardant Health
11.7.1 Guardant Health Company Detail
11.7.2 Guardant Health Business Overview
11.7.3 Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.7.4 Guardant Health Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2019-2024)
11.7.5 Guardant Health Recent Development
11.8 MGI Tech
11.8.1 MGI Tech Company Detail
11.8.2 MGI Tech Business Overview
11.8.3 MGI Tech Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.8.4 MGI Tech Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2019-2024)
11.8.5 MGI Tech Recent Development
11.9 Amoy Diagnostics
11.9.1 Amoy Diagnostics Company Detail
11.9.2 Amoy Diagnostics Business Overview
11.9.3 Amoy Diagnostics Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.9.4 Amoy Diagnostics Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2019-2024)
11.9.5 Amoy Diagnostics Recent Development
11.10 BGI Group
11.10.1 BGI Group Company Detail
11.10.2 BGI Group Business Overview
11.10.3 BGI Group Pharmacogenomics Technology (Theranostics & CDx) Introduction
11.10.4 BGI Group Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2019-2024)
11.10.5 BGI Group Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Instruments
Table 3. Key Players of Reagents and Consumables
Table 4. Key Players of Other
Table 5. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Region (2019-2024)
Table 9. Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Region (2025-2030)
Table 11. Pharmacogenomics Technology (Theranostics & CDx) Market Trends
Table 12. Pharmacogenomics Technology (Theranostics & CDx) Market Drivers
Table 13. Pharmacogenomics Technology (Theranostics & CDx) Market Challenges
Table 14. Pharmacogenomics Technology (Theranostics & CDx) Market Restraints
Table 15. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Players (2019-2024)
Table 17. Global Top Pharmacogenomics Technology (Theranostics & CDx) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmacogenomics Technology (Theranostics & CDx) as of 2023)
Table 18. Ranking of Global Top Pharmacogenomics Technology (Theranostics & CDx) Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Pharmacogenomics Technology (Theranostics & CDx) Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Pharmacogenomics Technology (Theranostics & CDx) Product Solution and Service
Table 22. Date of Enter into Pharmacogenomics Technology (Theranostics & CDx) Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Type (2019-2024)
Table 26. Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Type (2025-2030)
Table 28. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Application (2019-2024)
Table 30. Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Application (2025-2030)
Table 32. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2025-2030) & (US$ Million)
Table 47. Illumina Company Detail
Table 48. Illumina Business Overview
Table 49. Illumina Pharmacogenomics Technology (Theranostics & CDx) Product
Table 50. Illumina Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2019-2024) & (US$ Million)
Table 51. Illumina Recent Development
Table 52. F. Hoffmann-La Roche Company Detail
Table 53. F. Hoffmann-La Roche Business Overview
Table 54. F. Hoffmann-La Roche Pharmacogenomics Technology (Theranostics & CDx) Product
Table 55. F. Hoffmann-La Roche Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2019-2024) & (US$ Million)
Table 56. F. Hoffmann-La Roche Recent Development
Table 57. Agilent Company Detail
Table 58. Agilent Business Overview
Table 59. Agilent Pharmacogenomics Technology (Theranostics & CDx) Product
Table 60. Agilent Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2019-2024) & (US$ Million)
Table 61. Agilent Recent Development
Table 62. Abbott Company Detail
Table 63. Abbott Business Overview
Table 64. Abbott Pharmacogenomics Technology (Theranostics & CDx) Product
Table 65. Abbott Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2019-2024) & (US$ Million)
Table 66. Abbott Recent Development
Table 67. Thermo Fisher Scientific Company Detail
Table 68. Thermo Fisher Scientific Business Overview
Table 69. Thermo Fisher Scientific Pharmacogenomics Technology (Theranostics & CDx) Product
Table 70. Thermo Fisher Scientific Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2019-2024) & (US$ Million)
Table 71. Thermo Fisher Scientific Recent Development
Table 72. Qiagen Company Detail
Table 73. Qiagen Business Overview
Table 74. Qiagen Pharmacogenomics Technology (Theranostics & CDx) Product
Table 75. Qiagen Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2019-2024) & (US$ Million)
Table 76. Qiagen Recent Development
Table 77. Guardant Health Company Detail
Table 78. Guardant Health Business Overview
Table 79. Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Product
Table 80. Guardant Health Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2019-2024) & (US$ Million)
Table 81. Guardant Health Recent Development
Table 82. MGI Tech Company Detail
Table 83. MGI Tech Business Overview
Table 84. MGI Tech Pharmacogenomics Technology (Theranostics & CDx) Product
Table 85. MGI Tech Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2019-2024) & (US$ Million)
Table 86. MGI Tech Recent Development
Table 87. Amoy Diagnostics Company Detail
Table 88. Amoy Diagnostics Business Overview
Table 89. Amoy Diagnostics Pharmacogenomics Technology (Theranostics & CDx) Product
Table 90. Amoy Diagnostics Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2019-2024) & (US$ Million)
Table 91. Amoy Diagnostics Recent Development
Table 92. BGI Group Company Detail
Table 93. BGI Group Business Overview
Table 94. BGI Group Pharmacogenomics Technology (Theranostics & CDx) Product
Table 95. BGI Group Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2019-2024) & (US$ Million)
Table 96. BGI Group Recent Development
Table 97. Research Programs/Design for This Report
Table 98. Key Data Information from Secondary Sources
Table 99. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Type: 2023 VS 2030
Figure 3. Instruments Features
Figure 4. Reagents and Consumables Features
Figure 5. Other Features
Figure 6. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Application: 2023 VS 2030
Figure 8. Tumour Case Studies
Figure 9. Diabetes Case Studies
Figure 10. Mental Illness Case Studies
Figure 11. Cardiovascular Disease Case Studies
Figure 12. Other Case Studies
Figure 13. Pharmacogenomics Technology (Theranostics & CDx) Report Years Considered
Figure 14. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 15. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Region: 2023 VS 2030
Figure 17. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Players in 2023
Figure 18. Global Top Pharmacogenomics Technology (Theranostics & CDx) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pharmacogenomics Technology (Theranostics & CDx) as of 2023)
Figure 19. The Top 10 and 5 Players Market Share by Pharmacogenomics Technology (Theranostics & CDx) Revenue in 2023
Figure 20. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. North America Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country (2019-2030)
Figure 22. United States Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Canada Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country (2019-2030)
Figure 26. Germany Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. France Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. U.K. Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Italy Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Russia Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Nordic Countries Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Share by Region (2019-2030)
Figure 34. China Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Japan Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. South Korea Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Southeast Asia Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. India Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Australia Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country (2019-2030)
Figure 42. Mexico Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Brazil Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Share by Country (2019-2030)
Figure 46. Turkey Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Saudi Arabia Pharmacogenomics Technology (Theranostics & CDx) Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Illumina Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2019-2024)
Figure 49. F. Hoffmann-La Roche Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2019-2024)
Figure 50. Agilent Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2019-2024)
Figure 51. Abbott Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2019-2024)
Figure 52. Thermo Fisher Scientific Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2019-2024)
Figure 53. Qiagen Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2019-2024)
Figure 54. Guardant Health Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2019-2024)
Figure 55. MGI Tech Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2019-2024)
Figure 56. Amoy Diagnostics Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2019-2024)
Figure 57. BGI Group Revenue Growth Rate in Pharmacogenomics Technology (Theranostics & CDx) Business (2019-2024)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
